| 0 (0%) | 09-27 09:32 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.26 | 1-year : | 2.63 |
| Resists | First : | 1.93 | Second : | 2.26 |
| Pivot price | 1.61 |
|||
| Supports | First : | 1.1 |
Second : | 0.59 |
| MAs | MA(5) : | 1.68 |
MA(20) : | 1.56 |
| MA(100) : | 0.8 |
MA(250) : | 1.07 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 65.3 |
D(3) : | 64.8 |
| RSI | RSI(14): 70.6 |
|||
| 52-week | High : | 3.98 | Low : | 0.23 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RLMD ] has closed above the upper band by 15.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 28% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.81 - 1.82 | 1.82 - 1.82 |
| Low: | 1.6 - 1.61 | 1.61 - 1.62 |
| Close: | 1.8 - 1.81 | 1.81 - 1.82 |
Tue, 23 Sep 2025
Relmada Therapeutics, Inc. (RLMD) Advances Oncology and CNS Therapies with Promising Phase 2 Data - Yahoo Finance
Wed, 17 Sep 2025
Relmada Therapeutics Regains Nasdaq Compliance - MSN
Tue, 16 Sep 2025
Clinical-Stage Biotech Relmada Therapeutics Secures Future on Nasdaq After Meeting Listing Requirements - Stock Titan
Tue, 02 Sep 2025
Tuesday 9/2 Insider Buying Report: RLMD, STRA - Nasdaq
Sun, 31 Aug 2025
Relmada Therapeutics Stock (RLMD) Opinions on Clinical Trial Results and Insider Buying - Quiver Quantitative
Sat, 30 Aug 2025
Relmada Therapeutics Sees Stock Uptick Amid Strategic Developments - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 33 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 18.8 (%) |
| Held by Institutions | 34.3 (%) |
| Shares Short | 557 (K) |
| Shares Short P.Month | 401 (K) |
| EPS | -2.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.47 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -95.7 % |
| Return on Equity (ttm) | -175.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.83 |
| PEG Ratio | 0 |
| Price to Book value | 3.77 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|